Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)
Status:
Not yet recruiting
Trial end date:
2030-12-15
Target enrollment:
Participant gender:
Summary
RATIONALE: According to previous results from PHARE study, a subgroup of patients with
low-risk cancer (< 3 cm) without axillary lymph node involvement or small (< 2 cm) with
minimal lymph node involvement (1 positive node) presented low risk of recurrence.
Maintaining chemotherapy in this subgroup could cause toxicity and it is not yet known
whether giving trastuzumab as monotherapy in neoadjuvant setting is as effective as giving
trastuzumab combined with paclitaxel in patients with low risk early breast cancer.
PURPOSE: This randomized phase III trial is studying trastuzumab as monotherapy in
neoadjuvant setting to see if this treatment regimen is as efficient compared to trastuzumab
combination with paclitaxel chemotherapy in treating women with low risk (tumor size< 3 cm,
N0) early breast cancer.